FDA Accepts LEQEMBI (Lecanemab-Irmb) Biologics License Application For Subcutaneous Maintenance Dosing For The Treatment Of Early Alzheimer's Disease
( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...
ahajournals.org21d
Evaluating Vascular Hemodynamics in Cerebral Proliferative Angiopathy Using Advanced Arterial Spin Labeling MRI
Cerebral proliferative angiopathy (CPA) is a rare vascular disorder that affects normal blood circulation in the brain. Although the structural changes in CPA can be characterized using standard ...
BioSpace1mon
Amyloid Hypothesis in Doubt as Newly Approved Drugs Hit Hurdles
Safety is another challenge for antibodies targeting Aβ, in particular, amyloid-related imaging abnormalities (ARIA), which are characterized by brain swelling and can lead to death. Anti-amyloid ...
ahajournals.org1mon
Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association
in the walls of cerebral blood vessels as cerebral amyloid angiopathy (CAA), leading to vascular injury and extravasation of fluid (ARIA in the form of vasogenic edema) or red blood cells (ARIA in the ...
Medscape1y
Bad Blood: Could Brain Bleeds Be Contagious?
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...